Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486559 · ClinicalTrials.gov registry record · NA
The ECMO-Free Trial
A NA study of Extracorporeal Membrane Oxygenation Complication, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 225
- Enrollment target
- 8
- Study locations
NCT05486559: Active NA study of Extracorporeal Membrane Oxygenation Complication, sponsored by Vanderbilt University Medical Center.
NCT05486559 is a NA study of Extracorporeal Membrane Oxygenation Complication that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 225 participants, below the 810-participant average among 8 other Extracorporeal Membrane Oxygenation Complication trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486559, a NA study of Extracorporeal Membrane Oxygenation Complication, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 225 participants
- Enrollment target
- 8
- Study locations
Study Summary
Decannulation from venovenous extracorporeal membrane oxygenation (VV-ECMO) at the earliest and safest time would be expected to improve outcomes and reduce cost. Daily assessments for readiness to liberate from therapies have demonstrated success in other realms of critical care. A recent single-center study demonstrated that a protocolized daily assessment of readiness for liberation from VV-ECMO was feasible and did not raise any major safety concerns, but the effect of this protocolized daily assessment on clinical outcomes remains unclear. Further, the manner in which ECMO is provided, weaned, and discontinued varies significantly between centers, raising persistent concerns regarding widespread adoption of protocolized daily assessment of readiness for liberation from VV-ECMO. Data from large a randomized controlled trial is needed to compare the effects of a protocolized daily assessment of readiness for liberation from VV-ECMO versus usual care on duration of ECMO support and other clinical outcomes.
Primary Outcome
The primary outcome will be the time (in days) from randomization (time zero) until the time of the final successful discontinuation of ECMO. Discontinuation of ECMO will be considered to be successful if a patient undergoes decannulation and survives without ECMO until day 60. For patients who are decannulated and subsequently experience recannulation, the time of successful discontinuation of ECMO will be based on the final decannulation. Data collection will cease at the time of hospital disc
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER ECMO-free protocol
Study Locations (8)
California
- UC San Diego Health - San Diego
- Stanford University - Stanford
Texas
- Baylor University Medical Center - Dallas
- Texas Tech University Health Sciences Center of El Paso - El Paso
Minnesota
- Hennepin County Medical Center - Minneapolis
Tennessee
- Vanderbilt University Medical Center - Nashville
Utah
- University of Utah Health - Salt Lake City
Ontario
- Toronto General Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2026-04-18 |
| Phase | NA |
What the registry record for NCT05486559 still lists
NCT05486559 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 810-participant average among 8 other Extracorporeal Membrane Oxygenation Complication trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Extracorporeal Membrane Oxygenation Complication appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT05486559 lists 8 locations in 6 states (California, Texas, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05486559 about?
NCT05486559 is a clinical study titled "The ECMO-Free Trial". Decannulation from venovenous extracorporeal membrane oxygenation (VV-ECMO) at the earliest and safest time would be expected to improve outcomes and reduce cost. Daily assessments for readiness to liberate from therapies have demonstrated success in other realms of critical care. A recent single-ce...
What is the current status of trial NCT05486559?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 225 participants. The study started on 2022-09-07. Estimated completion is 2026-04-18.
What conditions does trial NCT05486559 study?
This clinical trial studies the following conditions: Extracorporeal Membrane Oxygenation Complication.
What interventions are being tested in trial NCT05486559?
The interventions under investigation include: Usual Care (OTHER), ECMO-free protocol (OTHER).
Who is sponsoring clinical trial NCT05486559?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486559 being conducted?
This trial has 8 study locations across California, Minnesota, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extracorporeal Membrane Oxygenation Complication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486559's enrollment target sits among peer trials
225 2nd of 8 the highest of 8 other Extracorporeal Membrane Oxygenation Complication trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Extracorporeal Membrane Oxygenation Complication trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Platform of Randomized Adaptive Clinical Trials in Critical Illness
RECRUITING · NA
-
Transplantation of Autologously Derived Mitochondria Following Ischemia
RECRUITING · NA
-
Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients
RECRUITING · NA
-
ECMO ABI Detection With Hyperfine
RECRUITING · NA
-
Low-Field Bedside Brain Magnetic Resonance Imaging in Pediatric Extracorporeal Membrane Oxygenation
COMPLETED · NA
-
The Effect of ECMO on the Pharmacokinetics of the Drugs and Their Clinical Efficacy
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI